<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HBC25AFAE89D44B5FA4D3EC277DC55F3A" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 6710 IH: To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-02-11</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 6710</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220211">February 11, 2022</action-date><action-desc><sponsor name-id="H001084">Ms. Herrell</sponsor> (for herself, <cosponsor name-id="B001299">Mr. Banks</cosponsor>, <cosponsor name-id="M001180">Mr. McKinley</cosponsor>, <cosponsor name-id="H001082">Mr. Hern</cosponsor>, <cosponsor name-id="M001211">Mrs. Miller of Illinois</cosponsor>, <cosponsor name-id="H001077">Mr. Higgins of Louisiana</cosponsor>, <cosponsor name-id="M001215">Mrs. Miller-Meeks</cosponsor>, <cosponsor name-id="S001189">Mr. Austin Scott of Georgia</cosponsor>, <cosponsor name-id="D000032">Mr. Donalds</cosponsor>, <cosponsor name-id="C001104">Mr. Cawthorn</cosponsor>, <cosponsor name-id="N000190">Mr. Norman</cosponsor>, <cosponsor name-id="L000266">Mr. LaTurner</cosponsor>, <cosponsor name-id="K000395">Mr. Keller</cosponsor>, <cosponsor name-id="H001067">Mr. Hudson</cosponsor>, <cosponsor name-id="C001039">Mrs. Cammack</cosponsor>, and <cosponsor name-id="G000552">Mr. Gohmert</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.</official-title></form><legis-body id="H4FDF3DA875954641935DEFF8F0DBCC8A" style="OLC"><section id="H7803FBBB97874BBEA002424E5CDA44A1" section-type="section-one"><enum>1.</enum><header>Report and recommendation on barriers to domestic manufacturing of medical products</header><subsection id="HF428FFAB3E184EA2B3B21182CB16F4BA"><enum>(a)</enum><header>Report to Congress</header><text display-inline="yes-display-inline">Not later than 180 days after the date of the enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the “Secretary”), acting through the Commissioner of Food and Drugs, shall submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices that are—</text><paragraph id="H328494DED910435EB6188CE013AF31D9"><enum>(1)</enum><text display-inline="yes-display-inline">imported from outside of the United States; and</text></paragraph><paragraph id="HE614151EE78E404BA0D71426FD4C97E1"><enum>(2)</enum><text>critical to the public health during a public health emergency declared by the Secretary under section 319 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d">42 U.S.C. 247d</external-xref>).</text></paragraph></subsection><subsection id="H7DB345CF344B4297AF625DC765F5C2EA"><enum>(b)</enum><header>Content</header><text display-inline="yes-display-inline">Such report shall—</text><paragraph id="HE40D1E2B53874327B9BD9901FBBEE40A"><enum>(1)</enum><text>identify factors that limit the manufacturing of active pharmaceutical ingredients, finished drug products, and devices described in subsection (a); and</text></paragraph><paragraph id="HFE557A6545734884B52D2F1F4BB8A34F"><enum>(2)</enum><text>recommend specific strategies to overcome the challenges identified under paragraph (1).</text></paragraph></subsection><subsection id="H57298C4729CB488D98EBD2A8EE1FAC13"><enum>(c)</enum><header>Implementation</header><text display-inline="yes-display-inline">The Secretary may, to the extent appropriate, implement the strategies recommended under subsection (b)(2).</text></subsection><subsection id="H77C67D8D5E404C01B110B76D463F12E9"><enum>(d)</enum><header>Definition</header><text>In this section, the term <quote>active pharmaceutical ingredient</quote> has the meaning given to such term in section 744A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-41">21 U.S.C. 379j–41</external-xref>).</text></subsection></section></legis-body></bill> 

